A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19

COVID-19 is caused by SARS-CoV-2, which originated in Wuhan, Hubei province, Central China, in December 2019 and since then has spread rapidly, resulting in a severe pandemic. The infected patient presents with varying non-specific symptoms requiring an accurate and rapid diagnostic tool to detect SARS-CoV-2. This is followed by effective patient isolation and early treatment initiation ranging from supportive therapy to specific drugs such as corticosteroids, antiviral agents, antibiotics, and the recently introduced convalescent plasma. The development of an efficient vaccine has been an on-going challenge by various nations and research companies. A literature search was conducted in early December 2020 in all the major databases such as Medline/PubMed, Web of Science, Scopus and Google Scholar search engines. The findings are discussed in three main thematic areas namely diagnostic approaches, therapeutic options, and potential vaccines in various phases of development. Therefore, an effective and economical vaccine remains the only retort to combat COVID-19 successfully to save millions of lives during this pandemic. However, there is a great scope for further research in discovering cost-effective and safer therapeutics, vaccines and strategies to ensure equitable access to COVID-19 prevention and treatment services.

[1]  K. Iwata,et al.  Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study , 2020, Clinical Epidemiology and Global Health.

[2]  J. V. Van Eyk,et al.  BCG vaccination history associates with decreased SARS-CoV-2 seroprevalence across a diverse cohort of healthcare workers. , 2020, The Journal of clinical investigation.

[3]  É. A. Silveira,et al.  BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial , 2020, Trials.

[4]  E. Walsh,et al.  Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.

[5]  R. Baric,et al.  Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults , 2020, The New England journal of medicine.

[6]  M. Netea,et al.  Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly , 2020, Cell.

[7]  T. Vekov,et al.  Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2 , 2020, Biomedicine & Pharmacotherapy.

[8]  W. Deng,et al.  Advances in research on ACE2 as a receptor for 2019-nCoV , 2020, Cellular and Molecular Life Sciences.

[9]  S. El-Kafrawy,et al.  Mortality in COVID-19 disease patients: Correlating the association of major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (SARS-CoV-2) variants , 2020, International Journal of Infectious Diseases.

[10]  Caitlin E. Anderson,et al.  SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents , 2020, Analytical chemistry.

[11]  A. Sahoo,et al.  Ivermectin: potential candidate for the treatment of Covid 19 , 2020, The Brazilian Journal of Infectious Diseases.

[12]  Anoop Misra,et al.  Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[13]  A. Aouba,et al.  Anakinra for patients with COVID-19 , 2020, The Lancet Rheumatology.

[14]  M. Massari,et al.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study , 2020, The Lancet Rheumatology.

[15]  P. Lotti,et al.  Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study , 2020, The Journal of Infection.

[16]  A. Hess,et al.  Hospitalized COVID-19 patients treated with Convalescent Plasma in a mid-size city in the midwest , 2020, medRxiv.

[17]  M. Al-Jaghbeer,et al.  Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study , 2020, EClinicalMedicine.

[18]  A. Ranade,et al.  Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19) , 2020, Postgraduate Medical Journal.

[19]  F. Palumbo,et al.  Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia , 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[20]  C. S. Kow,et al.  Use of low-molecular-weight heparin in COVID-19 patients , 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[21]  Martina Capuzzo,et al.  Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays , 2020, Reproductive BioMedicine Online.

[22]  Marlin Touma COVID-19: molecular diagnostics overview , 2020, Journal of Molecular Medicine.

[23]  Suchi Goel,et al.  Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials , 2020, Journal of Biosciences.

[24]  Reza Gharebaghi MD MPH FAAO PhDc,et al.  Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen , 2020, The Journal of Antibiotics.

[25]  L. Ren,et al.  Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[26]  S. Kumar,et al.  Battle against COVID-19: Efficacy of Convalescent Plasma as an emergency therapy , 2020, The American Journal of Emergency Medicine.

[27]  T. Burki Testing for COVID-19 , 2020, The Lancet Respiratory Medicine.

[28]  Adewale Owa,et al.  Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial? , 2020, Journal of Microbiology, Immunology and Infection.

[29]  J. Kim,et al.  Immunogenicity of a DNA vaccine candidate for COVID-19 , 2020, Nature Communications.

[30]  E. Coomes,et al.  Favipiravir, an antiviral for COVID-19? , 2020, The Journal of antimicrobial chemotherapy.

[31]  E. Wood,et al.  Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. , 2020, The Cochrane database of systematic reviews.

[32]  Anoop Misra,et al.  Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[33]  Renyi Wu,et al.  An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.

[34]  G. Costantino,et al.  Use of anakinra in severe COVID-19: A case report , 2020, International Journal of Infectious Diseases.

[35]  C. Godugu,et al.  The current understanding and potential therapeutic options to combat COVID-19 , 2020, Life Sciences.

[36]  Alla Turshudzhyan Anticoagulation Options for Coronavirus Disease 2019 (COVID-19)-Induced Coagulopathy , 2020, Cureus.

[37]  W. Simonson Vitamin C and coronavirus , 2020, Geriatric Nursing.

[38]  G. Catho,et al.  COVID-19: don't neglect antimicrobial stewardship principles! , 2020, Clinical Microbiology and Infection.

[39]  Hongjun Li,et al.  Clinical and imaging features of COVID-19 , 2020, Radiology of Infectious Diseases.

[40]  Ssang-Goo Cho,et al.  COVID-19: an update on diagnostic and therapeutic approaches , 2020, BMB reports.

[41]  Shubing Zhang,et al.  The genetic sequence, origin, and diagnosis of SARS-CoV-2 , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[42]  Keshav Rajarshi,et al.  Combating COVID-19 with mesenchymal stem cell therapy , 2020, Biotechnology Reports.

[43]  E. Nicastri,et al.  Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact , 2020, Journal of Infection.

[44]  A. Boretti,et al.  Intravenous vitamin C for reduction of cytokines storm in acute respiratory distress syndrome , 2020, PharmaNutrition.

[45]  T. A. Abd El-Aziz,et al.  Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status , 2020, Infection, Genetics and Evolution.

[46]  Dena Goffman,et al.  Universal Screening for SARS-CoV-2 in Women Admitted for Delivery , 2020, The New England journal of medicine.

[47]  A. Ardeshirylajimi,et al.  Mesenchymal Stem Cell Therapy for COVID-19: Present or Future , 2020, Stem Cell Reviews and Reports.

[48]  B. Liang,et al.  Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis , 2020, Journal of Infection.

[49]  Shinji Makino,et al.  An Infectious cDNA Clone of SARS-CoV-2 , 2020, Cell Host & Microbe.

[50]  N. Moore Chloroquine for COVID-19 Infection , 2020, Drug Safety.

[51]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[52]  M. Day Covid-19: four fifths of cases are asymptomatic, China figures indicate , 2020, BMJ.

[53]  P. Vollmar,et al.  Virological assessment of hospitalized patients with COVID-2019 , 2020, Nature.

[54]  Chengliang Zhu,et al.  The comparative superiority of IgM-IgG antibody test to real-time reverse transcriptase PCR detection for SARS-CoV-2 infection diagnosis , 2020, medRxiv.

[55]  T. West,et al.  Covid-19 in Critically Ill Patients in the Seattle Region — Case Series , 2020, The New England journal of medicine.

[56]  Heng Li,et al.  Coronavirus disease 2019 (COVID-19): current status and future perspectives , 2020, International Journal of Antimicrobial Agents.

[57]  Anoop Misra,et al.  Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries , 2020, Diabetes & Metabolic Syndrome: Clinical Research & Reviews.

[58]  Wu Zhong,et al.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.

[59]  E. Holmes,et al.  The proximal origin of SARS-CoV-2 , 2020, Nature Medicine.

[60]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[61]  W. Tang,et al.  Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. , 2020, European review for medical and pharmacological sciences.

[62]  Feng-hua Chen,et al.  Blood transfusion during the COVID-19 outbreak. , 2020, Blood transfusion = Trasfusione del sangue.

[63]  G. Chowell,et al.  Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[64]  Shaoqiang Li,et al.  Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis , 2020, Journal of medical virology.

[65]  M. Müller,et al.  Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform , 2020, Nature.

[66]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[67]  Malik Peiris,et al.  Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia , 2020, Clinical chemistry.

[68]  M. Ciccozzi,et al.  The 2019‐new coronavirus epidemic: Evidence for virus evolution , 2020, bioRxiv.

[69]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[70]  Michael J. Loeffelholz,et al.  Laboratory diagnosis of emerging human coronavirus infections – the state of the art , 2020, Emerging microbes & infections.

[71]  Chuan Qin,et al.  From SARS to MERS, Thrusting Coronaviruses into the Spotlight , 2019, Viruses.

[72]  A. Khojasteh,et al.  The Clinical Trials of Mesenchymal Stem Cell Therapy in Skin Diseases: An Update and Concise Review. , 2019, Current stem cell research & therapy.

[73]  I. Sola,et al.  Molecular Basis of Coronavirus Virulence and Vaccine Development , 2016, Advances in Virus Research.

[74]  Jing Xie,et al.  Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.

[75]  K. Singh,et al.  The clinical development process for a novel preventive vaccine: An overview , 2016, Journal of postgraduate medicine.

[76]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[77]  H. Fausther-Bovendo,et al.  Pre-existing immunity against Ad vectors , 2014, Human vaccines & immunotherapeutics.

[78]  Antonio Pérez,et al.  Glucocorticoid‐induced hyperglycemia (糖皮质激素诱导的高血糖) , 2014, Journal of diabetes.

[79]  N. Marwaha,et al.  Nucleic acid testing-benefits and constraints , 2014, Asian journal of transfusion science.

[80]  K. Bojang,et al.  A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity , 2012, PloS one.

[81]  Y. Takashima,et al.  Artificial molecular clamp: a novel device for synthetic polymerases. , 2011, Angewandte Chemie.

[82]  Larry J. Anderson,et al.  Real-Time Reverse Transcription–Polymerase Chain Reaction Assay for SARS-associated Coronavirus , 2004, Emerging infectious diseases.

[83]  H. Hemilä Vitamin C and SARS coronavirus , 2003, The Journal of antimicrobial chemotherapy.